Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy

Acute Myeloid Leukemia, Version 2.2013

(2017) Margaret R. O’Donnell et al.   Journal of the National Comprehensive Cancer Network

RAD51 and XRCC3 Gene Polymorphisms and the Risk of Developing Acute Myeloid Leukemia

(2016) Mona S. Hamdy et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner

(2015) M. Mochizuki-Kashio et al.   BLOOD

An update of current treatments for adult acute myeloid leukemia

(2015) H. Dombret et al.   BLOOD

Cytosine modifications in myeloid malignancies

(2015) Kristen M. Meldi et al.   PHARMACOLOGY & THERAPEUTICS

Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors

(2015) Daniela Damiani et al.   Oncotarget

Molecular Genetic Markers in Acute Myeloid Leukemia

(2015) Sophia Yohe   Journal of Clinical Medicine

Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients

(2015) Elias Bou Samra et al.   Oncotarget

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)

(2015) Harald Herrmann et al.   Oncotarget

Overcoming treatment resistance in acute promyelocytic leukemia and beyond

(2015) Tsz Kan Fung et al.   Oncotarget

Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age

(2014) Anne S. Roug et al.   BRITISH JOURNAL OF HAEMATOLOGY

Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid Leukemia

(2014) Jeffery M. Klco et al.   CANCER CELL

DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance

(2014) Maria Teresa Esposito et al.   CHROMOSOMA

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

(2014) Robert K Hills et al.   LANCET ONCOLOGY

DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies

(2014) A P Im et al.   LEUKEMIA

Requirement for Parp-1 and DNA ligases 1 or 3 but not of Xrcc1 in chromosomal translocation formation by backup end joining

(2014) Aashish Soni et al.   NUCLEIC ACIDS RESEARCH

Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation

(2014) Goro Sashida et al.   Nature Communications

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

(2013) S. R. Daigle et al.   BLOOD

Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia

(2013) O. Abdel-Wahab et al.   BLOOD

PARP1 is required for chromosomal translocations

(2013) J. Wray et al.   BLOOD

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

(2013) S. H. Petersdorf et al.   BLOOD

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

(2013) F. Ravandi et al.   BLOOD

Polycomb Repressive Complex 2 Regulates Normal Hematopoietic Stem Cell Function in a Developmental-Stage-Specific Manner

(2013) Huafeng Xie et al.   Cell Stem Cell

Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies

(2013) T. J. Gaymes et al.   HAEMATOLOGICA

Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial

(2013) Hubert Serve et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

(2013) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies

(2013) S N Khan et al.   LEUKEMIA

XRCC1Arg194Trp and Arg399Gln polymorphisms are significantly associated with shorter survival in acute myeloid leukemia

(2013) Claudia Bănescu et al.   LEUKEMIA & LYMPHOMA

Expression of Leukemia-Associated Fusion Proteins Increases Sensitivity to Histone Deacetylase Inhibitor-Induced DNA Damage and Apoptosis

(2013) L. A. Petruccelli et al.   MOLECULAR CANCER THERAPEUTICS

Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition

(2013) Matteo Berti et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

(2013) Francesco Lo-Coco et al.   NEW ENGLAND JOURNAL OF MEDICINE

Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51

(2013) Chengzhi Xie et al.   PLoS One

XRCC1 Arg399Gln variation and leukemia susceptibility: evidence from 2,647 cases and 5,518 controls

(2013) Yi Huang et al.   TUMOR BIOLOGY

Mutant DNMT3A: teaming up to transform

(2012) C. Thiede   BLOOD

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia

(2012) A. F. T. Ribeiro et al.   BLOOD

Clinical and proteomic characterization of acute myeloid leukemia with mutatedRAS

(2012) Tapan M. Kadia et al.   CANCER

Evaluation of checkpoint kinase targeting therapy in Acute Myeloid Leukemia with complex karyotype

(2012) Christine Didier et al.   CANCER BIOLOGY & THERAPY

SnapShot: Acute Myeloid Leukemia

(2012) Bernd B. Zeisig et al.   CANCER CELL

IDH mutations in acute myeloid leukemia

(2012) Dinesh Rakheja et al.   HUMAN PATHOLOGY

TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group

(2012) Verena I. Gaidzik et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

(2012) R M Stone et al.   LEUKEMIA

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns

(2012) A S Moore et al.   LEUKEMIA

Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia

(2012) Magdalena Koszarska et al.   LEUKEMIA & LYMPHOMA

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription

(2012) M Maicas et al.   ONCOGENE

Model for MLL translocations in therapy-related leukemia involving topoisomerase II -mediated DNA strand breaks and gene proximity

(2012) I. G. Cowell et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease

(2012) A. Herrera-Merchan et al.   Nature Communications

Monosomal karyotype in acute myeloid leukemia defines a distinct subgroup within the adverse cytogenetic risk category

(2012) Georgia Voutiadou et al.   Cancer Genetics

Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities

(2011) A. Perrot et al.   BLOOD

Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies

(2011) S. Kayser et al.   BLOOD

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

(2011) Y. Shen et al.   BLOOD

The prognostic significance of IDH2 mutations in AML depends on the location of the mutation

(2011) C. L. Green et al.   BLOOD

Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells

(2011) M. Mochizuki-Kashio et al.   BLOOD

TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome

(2011) F. G. Rucker et al.   BLOOD

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics

(2011) W.-C. Chou et al.   BLOOD

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation

(2011) Kelly Moran-Crusio et al.   CANCER CELL

Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia

(2011) Claudia Haferlach et al.   GENES CHROMOSOMES & CANCER

Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission

(2011) M. Yanada et al.   HAEMATOLOGICA

Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications

(2011) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

TET2Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2011) Klaus H. Metzeler et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic Advances in Acute Myeloid Leukemia

(2011) Alan Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Landscape of TET2 mutations in acute myeloid leukemia

(2011) S Weissmann et al.   LEUKEMIA

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia

(2011) K H Metzeler et al.   LEUKEMIA

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

(2011) R Itzykson et al.   LEUKEMIA

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

Functional Connection between Rad51 and PML in Homology-Directed Repair

(2011) Sergei Boichuk et al.   PLoS One

Fanconi anemia and Bloom's syndrome crosstalk through FANCJ–BLM helicase interaction

(2011) Avvaru N. Suhasini et al.   TRENDS IN GENETICS

DNA Ligase III Promotes Alternative Nonhomologous End-Joining during Chromosomal Translocation Formation

(2011) Deniz Simsek et al.   PLoS Genetics

New Prognostic Markers in Acute Myeloid Leukemia: Perspective from the Clinic

(2011) J. M. Foran   Hematology-American Society of Hematology Education Program

Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring

(2010) Feng Xu et al.   ANNALS OF HEMATOLOGY

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status

(2010) S. Schnittger et al.   BLOOD

The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status

(2010) C. L. Green et al.   BLOOD

Opposing roles of polycomb repressive complexes in hematopoietic stem and progenitor cells

(2010) I. J. Majewski et al.   BLOOD

RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis

(2010) S. Schnittger et al.   BLOOD

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2010) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance ofCEBPAMutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of DoubleCEBPAMutations and the Interaction WithFLT3andNPM1Mutations

(2010) Claire L. Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

(2010) Stefan Gross et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients

(2010) Sara S. Strom et al.   LEUKEMIA & LYMPHOMA

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

(2010) Myunggon Ko et al.   NATURE

NHEJ and its backup pathways in chromosomal translocations

(2010) Michael R Lieber   NATURE STRUCTURAL & MOLECULAR BIOLOGY

An essential role for CtIP in chromosomal translocation formation through an alternative end-joining pathway

(2010) Yu Zhang et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

DNMT3AMutations in Acute Myeloid Leukemia

(2010) Timothy J. Ley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Array-based genomic resequencing of human leukemia

(2010) Y Yamashita et al.   ONCOGENE

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

(2009) K. W. Pratz et al.   BLOOD

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

(2009) O. Abdel-Wahab et al.   BLOOD

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations

(2009) J.-L. Tang et al.   BLOOD

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

(2009) B. J. Wouters et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy

(2009) C. Cavelier et al.   CANCER RESEARCH

EVI1 Impairs Myelopoiesis by Deregulation of PU.1 Function

(2009) Leopoldo Laricchia-Robbio et al.   CANCER RESEARCH

PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination

(2009) Helen E Bryant et al.   EMBO JOURNAL

Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes

(2009) T. J. Gaymes et al.   HAEMATOLOGICA

Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome

(2009) Annika Dufour et al.   JOURNAL OF CLINICAL ONCOLOGY

Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity

(2009) T. M. Horton et al.   MOLECULAR CANCER THERAPEUTICS

Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells

(2009) Andrea Viale et al.   NATURE

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

(2009) Elaine R. Mardis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1 

(2009) S. Zhao et al.   SCIENCE

Epigenetic Cross-Talk between DNA Methylation and Histone Modifications in Human Cancers

(2009) Yutaka Kondo   YONSEI MEDICAL JOURNAL

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

(2008) K. H. Metzeler et al.   BLOOD

High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated

(2008) S. Lugthart et al.   BLOOD

Preferential loss of mismatch repair function in refractory and relapsed acute myeloid leukemia: potential contribution to AML progression

(2008) Guogen Mao et al.   CELL RESEARCH

Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia

(2008) Lykke Grubach et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype

(2008) Dimitri A. Breems et al.   JOURNAL OF CLINICAL ONCOLOGY

Patients With Acute Myeloid Leukemia andRASMutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study

(2008) Andreas Neubauer et al.   JOURNAL OF CLINICAL ONCOLOGY

Dysregulation of the C/EBPα Differentiation Pathway in Human Cancer

(2008) Steffen Koschmieder et al.   JOURNAL OF CLINICAL ONCOLOGY

Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group

(2008) Thomas Büchner et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE